[Corrections] Correction to Lancet Oncol 2026; 27: 461–69
Summary
Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol 2026; 27: 461–69—In this Article, the title has been corrected to “[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study”. This correction has been made to the onlin…
Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol 2026; 27: 461–69—In this Article, the title has been corrected to “[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study”. This correction has been made to the online version as of April 27, 2026.